Faculty of Life Sciences, The University of Manchester, Manchester, United Kingdom.
J Cataract Refract Surg. 2013 Mar;39(3):451-62. doi: 10.1016/j.jcrs.2013.01.026.
Photodynamic collagen crosslinking (CXL) using ultraviolet-A (UVA) irradiation combined with the photosensitizer riboflavin has been introduced as a new treatment for progressive keratoconus. The results of clinical studies are promising, but the efficacy of the treatment in halting the progression depends on the stability of the induced biomechanical effects. The effects of corneal CXL on corneal rigidity; collagen fiber diameter; and resistance to heat degradation, enzymatic digestion, and swelling due to hydration are reviewed in this paper. The collective results indicate that CXL using UVA and riboflavin enhances the biomechanical properties of the corneal tissue, which remain stable over time. Therefore, this treatment could become the future standard therapy for keratoconus or used to halt the progression of keratoconus and postpone the need for corneal transplantation. The increase in availability and popularity of the CXL technique accentuates the requirement for reliable and accurate techniques for measuring corneal biomechanical properties before and after treatment.
光动力角膜胶原交联（CXL）使用紫外线-A（UVA）照射联合光增敏剂核黄素已被引入作为进行性圆锥角膜的一种新的治疗方法。临床研究的结果很有希望，但治疗停止进展的效果取决于诱导的生物力学效应的稳定性。本文综述了角膜 CXL 对角膜硬度、胶原纤维直径以及对热降解、酶消化和水合作用引起的膨胀的抵抗力的影响。综合结果表明，使用 UVA 和核黄素的 CXL 增强了角膜组织的生物力学特性，这些特性随时间保持稳定。因此，这种治疗方法可能成为圆锥角膜的未来标准治疗方法，或者用于阻止圆锥角膜的进展并推迟角膜移植的需要。CXL 技术的可用性和普及度的增加强调了在治疗前后测量角膜生物力学特性的可靠和准确技术的要求。
